Skip to Content

The future of targeted cell therapy against cancer

NKILT Therapeutics is redefining the future of cancer treatment with allogeneic and off-the-shelf cell therapy.

Tumor Cell
NK Cell

A cutting-edge cell therapy biotech in seed stage

NKILT Therapeutics is developing a novel allogeneic, off-the-shelf approach to engineering immune cells, starting with natural killer (NK) cells, to directly target leukemias and solid tumors.

A platform with exceptional potential

Our platform focuses initially on allogeneic NK cells through a completely unique and novel approach of natural receptor binding called Chimeric ILT-Receptor (CIR).

Our technology

Has potential in >50% of cancers

Our target, HLA-G, has broad expression across tumor types.

Morphs nature

Our CIR technology combines exquisite natural specificity with unique signaling.

Optimizes signal transduction

Our NK cells have longer activation in vivo.

Exploits tumor vulnerability

HLA-G is found in both the tumor and the inhibitory tumor microenvironment (TME).

We anticipate further developing our CIR technology through other immune cells, such as T cells and invariant natural killer T (iNKT) cells.

Delve into the science

Our engineered NK cells will not only directly kill cancer cells but also activate innate and adaptive immunity and directly target tumor defense mechanisms.

The latest from NKILT

Check back soon to see what’s new. In the meantime, visit our LinkedIn page for updates.

Interested? Let’s talk.

Find out how you can join us in building the future of cell therapy.

    * Required field.

    Message frequency may vary. You may opt out at any time.

    Terms and Conditions and Privacy Policy.